Aditya Bagrodia

And like you said, you know, earlier PSMA PET scanning has kind of flipped everything on its head when it comes to detecting METs. Well, you know, I think this is a topic that can be reviewed enough.

And like you said, you know, earlier PSMA PET scanning has kind of flipped everything on its head when it comes to detecting METs. Well, you know, I think this is a topic that can be reviewed enough.

I mean, I certainly learn plenty every time and, you know, not to, I absolutely think that a lot of people, you know, med-oncs, radoncs, urologists can safely and effectively prescribe ADT, but it behooves us to kind of stay up with it, make sure patients are well-informed and, you know, do everything we can at our end as well as the patient and to help mitigate side effects.

I mean, I certainly learn plenty every time and, you know, not to, I absolutely think that a lot of people, you know, med-oncs, radoncs, urologists can safely and effectively prescribe ADT, but it behooves us to kind of stay up with it, make sure patients are well-informed and, you know, do everything we can at our end as well as the patient and to help mitigate side effects.

I mean, I certainly learn plenty every time and, you know, not to, I absolutely think that a lot of people, you know, med-oncs, radoncs, urologists can safely and effectively prescribe ADT, but it behooves us to kind of stay up with it, make sure patients are well-informed and, you know, do everything we can at our end as well as the patient and to help mitigate side effects.

So maybe as we're kind of wrapping up here, Raina, any kind of parting thoughts for the audience on how you approach ADT or things you're excited about in the future?

So maybe as we're kind of wrapping up here, Raina, any kind of parting thoughts for the audience on how you approach ADT or things you're excited about in the future?

So maybe as we're kind of wrapping up here, Raina, any kind of parting thoughts for the audience on how you approach ADT or things you're excited about in the future?

That sounds perfect, Raina. Well, thank you, as always, for your keen insights. Always a pleasure. And best of luck with the ASCO elections. Again, Raina is on the nominating committee. She's amazing. Vote for her. All right, Raina. Thank you so much.

That sounds perfect, Raina. Well, thank you, as always, for your keen insights. Always a pleasure. And best of luck with the ASCO elections. Again, Raina is on the nominating committee. She's amazing. Vote for her. All right, Raina. Thank you so much.

That sounds perfect, Raina. Well, thank you, as always, for your keen insights. Always a pleasure. And best of luck with the ASCO elections. Again, Raina is on the nominating committee. She's amazing. Vote for her. All right, Raina. Thank you so much.

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on iTunes, Spotify, and at backtable.com. This is Aditya Bagrodia as your host this week, and I'm very excited to introduce our guest today, Bifar Adai from Memorial Sloan Kettering, Department of Urology. Bifar, how's it going today?

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on iTunes, Spotify, and at backtable.com. This is Aditya Bagrodia as your host this week, and I'm very excited to introduce our guest today, Bifar Adai from Memorial Sloan Kettering, Department of Urology. Bifar, how's it going today?

Hello, everyone, and welcome back to the Backtable podcast, your source for all things urology. You can find all previous episodes of our podcast on iTunes, Spotify, and at backtable.com. This is Aditya Bagrodia as your host this week, and I'm very excited to introduce our guest today, Bifar Adai from Memorial Sloan Kettering, Department of Urology. Bifar, how's it going today?

It's great to see you again, Aditya. Yeah, pleasure's all mine. You know, I had the good fortune of training under Bafar when I was a fellow there. Very, very thoughtful clinician, exquisite surgeon, and, you know, my opinion has... properly, methodically moved our field forward substantially, particularly with prostate cancer.

It's great to see you again, Aditya. Yeah, pleasure's all mine. You know, I had the good fortune of training under Bafar when I was a fellow there. Very, very thoughtful clinician, exquisite surgeon, and, you know, my opinion has... properly, methodically moved our field forward substantially, particularly with prostate cancer.

It's great to see you again, Aditya. Yeah, pleasure's all mine. You know, I had the good fortune of training under Bafar when I was a fellow there. Very, very thoughtful clinician, exquisite surgeon, and, you know, my opinion has... properly, methodically moved our field forward substantially, particularly with prostate cancer.

So today we're going to talk about, you know, the technical title is Novel Methods in Clinical Trials. And maybe I'll just extend that a bit into...

So today we're going to talk about, you know, the technical title is Novel Methods in Clinical Trials. And maybe I'll just extend that a bit into...

So today we're going to talk about, you know, the technical title is Novel Methods in Clinical Trials. And maybe I'll just extend that a bit into...